Generally, elevated ST6GAL1 and dysregulated α2,6-sialylation are prominently correlated with increased malignancy, especially in the lung, colorectal, pancreatic, and breast cancers [52, 53]. Here, ST6GAL1 is linked to breast carcinoma.